GlassScriptPhysician profile
Dayanand Makey
NPI 1760788368
$1,740.68
in general payments reported to CMS, 2019-2025
29 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356 · 2020: $243 · 2021: $137 · 2022: $104 · 2023: $279 · 2024: $116 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $881 · Education: $19.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $880.76 |
| Education | $19.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $214.66 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $198.18 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $168.23 | 2019-2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $146.10 | 2021-2023 | Lupkynis |
| Xeris Pharmaceuticals, INC. | $135.91 | 2025 | Keveyis |
| Amgen INC. | $116.67 | 2020-2023 | Tavneos, Epogen, Parsabiv |
| Mallinckrodt Enterprises LLC | $88.44 | 2019 | |
| Vifor Pharma, INC. | $82.49 | 2020-2022 | |
| Akebia Therapeutics INC | $76.56 | 2019-2021 | |
| Opko Pharmaceuticals, LLC | $54.11 | 2019 | |
| Calliditas Therapeutics US INC. | $51.21 | 2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $42.43 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $36.11 | 2025 | Ultomiris |
| Mozarc Medical US LLC | $35.72 | 2023 | Chameleon |
| Daiichi Sankyo INC. | $33.76 | 2025 | Injectafer |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $31.51 | 2019-2021 | |
| Baxter Healthcare | $30.81 | 2019-2024 | Renal - Crrt |
| Kyowa Kirin, INC. | $23.06 | 2024 | Crysvita |
| W. L. Gore & Associates, INC. | $22.33 | 2020 | |
| Travere Therapeutics, INC. | $19.54 | 2023-2025 | Filspari |
| Lilly USA, LLC | $16.95 | 2023 | Jardiance |
| Glaxosmithkline, LLC. | $16.89 | 2023 | Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $15.53 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $15.17 | 2022 | |
| Nxstage Medical, INC. | $14.73 | 2021 | |
| Ardelyx, INC. | $14.61 | 2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.81 | 2022 | |
| Genentech USA, INC. | $12.67 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $12.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dayanand Makey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.